Literature DB >> 32211908

Functional and Morphologic Findings at Four Years After Intravitreal Bevacizumab or Laser for Type 1 ROP.

Domenico Lepore, Marco H Ji, Graham E Quinn, Giulia M Amorelli, Lorenzo Orazi, Daniela Ricci, Eugenio Mercuri.   

Abstract

BACKGROUND AND
OBJECTIVE: To compare morphologic and functional status at age 4 years for patients treated in one eye with laser photocoagulation and the other eye with intravitreal bevacizumab (IVB) injection for Type 1 retinopathy of prematurity (ROP). PATIENTS AND METHODS: In this single-center, randomized, controlled trial, best-corrected visual acuity (BCVA) in logMAR was obtained along with spherical equivalent refraction (SER), fluorescein angiography (FA), optical coherent tomography (OCT), and OCT angiography (OCTA).
RESULTS: Eighteen babies (36 eyes) were selected for this study. BCVA and SER were similar in the two groups, but six patients had anisometropia of 4 diopters or more. IVB-treated eyes tended to have thinner foveal thickness than laser-treated eyes (mean difference: -5.33 pixels; 95% confidence interval, -9.62 to -1.05).
CONCLUSION: Although the differences found here are minimal between the IVB-treated and laser-treated groups, further long-term evaluation of not only FA, but also OCT and OCTA, are needed in larger studies. [Ophthalmic Surg Lasers Imaging Retina. 2020;51:180-186.]. Copyright 2020, SLACK Incorporated.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 32211908     DOI: 10.3928/23258160-20200228-07

Source DB:  PubMed          Journal:  Ophthalmic Surg Lasers Imaging Retina        ISSN: 2325-8160            Impact factor:   1.300


  1 in total

1.  Comparison of Clinical Outcomes of Intravitreal Bevacizumab and Aflibercept in Type 1 Prethreshold Retinopathy of Prematurity in Posterior Zone II.

Authors:  Amir Eftekhari Milani; Masood Bagheri; Mohamad Reza Niyousha; Leila Rezaei; Somayyeh Hazeri; Samad Safarpoor; Maryam Abdollahi
Journal:  J Curr Ophthalmol       Date:  2022-04-16
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.